Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?

about

Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.Key drivers of biomedical innovation in cancer drug discovery.Role of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin Toxicities

P2860

Q38551764-7698EAF7-2B85-4D99-A613-BC1502886CBB Q41768010-643A45B6-6642-4E1E-BE3C-2C136DF558CC Q41835826-7E2E3C90-9FFA-4EE8-B08C-402BF415EFDD

P2860

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?

Item

http://www.wikidata.org/entity/Q38222703

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Which tyrosine kinase inhibito ...... patients with EGFR mutations?

@en

type

Item

label

Which tyrosine kinase inhibito ...... patients with EGFR mutations?

@en

prefLabel

Which tyrosine kinase inhibito ...... patients with EGFR mutations?

@en

P1476

Which tyrosine kinase inhibito ...... patients with EGFR mutations?

@en

P2093

Chiara Lazzari

http://www.w3.org/2001/XMLSchema#string

Rosa Lerose

http://www.w3.org/2001/XMLSchema#string

Vanesa Gregorc

http://www.w3.org/2001/XMLSchema#string

P2860

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

P2888

s12032-014-0078-5

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-014-0078-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

M Aieta

Alfredo Tartarone

P577

2014-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1001111007

http://www.w3.org/2001/XMLSchema#string

P698

24958518

http://www.w3.org/2001/XMLSchema#string

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?

about

P2860

P2860

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698